Walker M P, Moore T R, Brace R A
Department of Reproductive Medicine, University of California, San Diego.
Am J Obstet Gynecol. 1994 Nov;171(5):1234-41. doi: 10.1016/0002-9378(94)90139-2.
Indomethacin has been shown to cause fetal oliguria in humans and animals. This study was designed to test the hypothesis that indomethacin-induced fetal oliguria is mediated through the renal action of arginine vasopressin.
Twenty-seven late-gestation (129 +/- 4 days [mean +/- SE]) chronically catheterized fetal sheep were studied. After a 1-hour control period fetal responses to indomethacin, 0.05 mg/kg given intravenously, followed by a 4-hour maintenance infusion (n = 9), were compared with an identical indomethacin infusion plus an arginine vasopressin V2-receptor antagonist (d[CH2]1(5), D-Phe2, Ile4,Arg8,Ala9)-VP (n = 8) or vehicle alone (n = 10). Fetal arterial and venous pressures, heart rate, and urinary flow were measured continuously.
Fetal urinary flow rate (p < 0.0001) and free water clearance (p = 0.004) fell in response to indomethacin alone, but the addition of the arginine vasopressin V2-receptor antagonist blocked indomethacin's oliguric and free water effect. Urinary osmolality and sodium increased in both indomethacin and indomethacin+arginine vasopressin V2-receptor antagonist groups compared with vehicle (p < 0.05). Fetal arterial pressure increased in response to indomethacin, and the addition of the arginine vasopressin V2-receptor antagonist potentiated this response (p = 0.007).
These results suggest that (1) fetal oliguria secondary to indomethacin is mediated through the stimulation of the renal arginine vasopressin V2-receptor and (2) prostaglandin synthesis inhibition may play a role in renal tubular sodium handling. In addition, the arginine vasopressin V2-receptor plays a role in ameliorating the hypertensive response to indomethacin. We speculate that indomethacin stimulates circulating arginine vasopressin levels and enhances peripheral arginine vasopressin effects in the fetus, resulting in oliguria and hypertension.
吲哚美辛已被证明可导致人类和动物胎儿少尿。本研究旨在验证以下假设:吲哚美辛诱导的胎儿少尿是通过精氨酸加压素的肾脏作用介导的。
对27只妊娠晚期(129±4天[平均值±标准误])长期插管的胎羊进行研究。在1小时的对照期后,将静脉注射0.05mg/kg吲哚美辛后的胎儿反应,随后进行4小时维持输注(n = 9),与相同的吲哚美辛输注加精氨酸加压素V2受体拮抗剂(d[CH2]1(5),D-Phe2,Ile4,Arg8,Ala9)-VP(n = 8)或单独使用赋形剂(n = 10)进行比较。连续测量胎儿动脉和静脉压力、心率和尿流。
单独使用吲哚美辛时,胎儿尿流率(p < 0.0001)和自由水清除率(p = 0.004)下降,但添加精氨酸加压素V2受体拮抗剂可阻断吲哚美辛的少尿和自由水效应。与赋形剂组相比,吲哚美辛组和吲哚美辛+精氨酸加压素V2受体拮抗剂组的尿渗透压和钠含量均增加(p < 0.05)。吲哚美辛使胎儿动脉压升高,添加精氨酸加压素V2受体拮抗剂可增强这一反应(p = 0.007)。
这些结果表明,(1)吲哚美辛继发的胎儿少尿是通过刺激肾脏精氨酸加压素V2受体介导的,(2)前列腺素合成抑制可能在肾小管钠处理中起作用。此外,精氨酸加压素V2受体在减轻对吲哚美辛的高血压反应中起作用。我们推测吲哚美辛刺激胎儿循环中精氨酸加压素水平并增强外周精氨酸加压素效应,导致少尿和高血压。